AstraZeneca reported second-quarter 2026 core earnings of $2.63 per share, beating analyst expectations of $2.48, while total revenue reached $15.38 billion, narrowly missing the $15.39 billion consensus. The Cambridge-based pharmaceutical group maintained its full-year guidance for low double-digit core EPS growth and mid-to-high single-digit revenue expansion at constant exchange rates, alongside a long-term target of $80 billion in annual revenue by 2030.
First-half total revenue rose 6% year-on-year to $30.67 billion, driven by a 15% jump in oncology sales to $14.12 billion. The company reported a successful late-stage gastric cancer trial, though its drug ultomiris failed to meet the primary goal in a stem-cell transplant complication study. Farxiga sales declined 11% in the first half.
AstraZeneca increased R&D spending 5% to $3.7 billion during the period. Shares were down roughly 8% in 2026 as of the earnings report.